Cipla from manufacturing and selling a generic version of Novartis’ patented respiratory drug ‘INDACATEROL’(sold as ‘Onbrez’).The judgment is significant in that it acknowledges ‘public interest’ as a separate factor to be considered for grant of an interim injunction, although it was found to play no role in the case. The court rejected Cipla’s ‘public interest’ argument [...]
Cipla is adopting every tactical strategy to compel Novartis to negotiate royalty agreement and give him license to manufacture “Onbrez Breezhaler” at low cost in India. What is “Onbrez Breezhaler” ? This drug is treatment for bronchitis. Inhalation device is designed to deliver the medicine contained in the capsules.The EU approved the Onbrez Breezhaler [...]
Patents on pharmaceuticals are a contentious issue for many countries around the world, for the obvious reason that the average person in most countries can’t afford to pay for brand-name drugs. The patent battle over Glivec is, needless to say, bitter and complicated. The argument for providing a patent to glivec (imatinib mesylate), a [...]
